B. Lynne Parshall - 15 Apr 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: Director
Issuer ticker: IONS
Reported as of: 15 Apr 2026
Net transaction value: -$381,367
SEC form: 4
Accepted by SEC: 17 Apr 2026, 19:19:39 UTC
Prior SEC filing: 02 Mar 2026
Next SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: By: Patrick R. O?Neil, attorney-in-fact For: B. Lynne Parshall

Key filing fact

B. Lynne Parshall filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 17 Apr 2026.

Key facts

This page summarizes B. Lynne Parshall's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 17 Apr 2026, 19:19.

Change

Previous filing in this sequence was filed on 02 Mar 2026.
Current net transaction value: -$381,367.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001073385 Primary reporting owner

PARSHALL B LYNNE

Relationship: Director
Address: 2855 GAZELLE COURT, CARLSBAD
Signature: By: Patrick R. O?Neil, attorney-in-fact For: B. Lynne Parshall
Signature date: 17 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Sale

Transaction value: $340,265
Shares: -4,466
Change %: -7.9%
Price: $76.19
Shares after: 51,878
Date: 15 Apr 2026
Ownership: Direct
Footnotes: F1, F2

IONS transaction

Common Stock

Sale

Transaction value: $41,102
Shares: -534
Change %: -1%
Price: $76.97
Shares after: 51,344
Date: 15 Apr 2026
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on May 6, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.77 to $76.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.85 to $77.115 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.